Development of modified IGF-binding proteins as novel anti-cancer chemotherapeutics

开发修饰的 IGF 结合蛋白作为新型抗癌化疗药物

• 批准号: nhmrc : 298975
• 负责人: Prof Grant Booker
• 金额: $ 5.16万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-modified-igf-cancer-chemotherapeutics/82686
• 关键词: Development; modified; IGF; binding; proteins

We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof of concept in vivo in order to attract commercial funding for clinical trials.

我们建议通过联合应用一种蛋白质来隔离促进癌细胞对化疗耐药的生长因子，从而提高当前抗癌治疗的有效性。我们的目标是在减少副作用的同时，改善乳腺癌和结直肠癌的破坏性。我们的体外数据显示了这种新型协同治疗的有效性，它是这些生长因子的天然载体蛋白的一种改良形式。这项申请寻求资金，以便能够在体内进行概念验证，以便为临床试验吸引商业资金。